15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering X4 Pharmaceuticals Inc, 5 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $5.00 to $12.00 (about 2.4x), a sign of real disagreement on valuation. The average target of $10.00 sits 154% above the current $3.93. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.19 next quarter toward $-0.82 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy5100%
Hold00%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to X4 Pharmaceuticals Inc.
As of Jul, 5 of 5 firms rate XFOR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
XFOR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.19
Range $-0.27 – $-0.17 · 5 analysts · -72% YoY
Next period, 5 analysts expect X4 Pharmaceuticals Inc to earn $-0.19 a share (range $-0.27 – $-0.17), versus $-0.69 a year earlier. Full-year consensus is $-0.73, growing to $-0.82 the year after.
REVENUE · NEXT QUARTER
$2.3M
Range $1.5M – $2.7M · 5 analysts · +28% YoY
Revenue is expected to reach $2.3M (range $1.5M – $2.7M), +28.0% year-over-year. Full-year consensus is $9.6M, rising to $10.3M next year.
Top analysts covering X4 Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on XFOR.
#1
Michael Schmidt
Guggenheim · Rank #1
Buy
$12.00+205.3% to target
Overall win rate
55%
+ Follow
#2
Kristen Kluska
Cantor Fitzgerald · Rank #162
Buy
$14.00+256.2% to target
Overall win rate
38%
+ Follow
#3
Swayampakula Ramakanth
HC Wainwright & Co. · Rank #230
Buy
$5.00+27.2% to target
Overall win rate
37%
+ Follow
#4
Derek Archila
Wells Fargo · Rank #350
Buy
$11.00+179.9% to target
Overall win rate
32%
+ Follow
#5
JC
James Condulis
Stifel
Buy
$10.00+154.5% to target
Coverage
—
+ Follow
XFOR stock forecast FAQ
What is XFOR's average 12-month price target?+
The 5 analysts with a live target average $10.00 for X4 Pharmaceuticals Inc over the next 12 months, ranging from a $12.00 high to a $5.00 low.
Is XFOR stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 5 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for XFOR?+
The Street-high target is $12.00 (Leerink Partners), and the Street-low is $5.00 (HC Wainwright & Co.). The average of all 5 active targets is $10.00.
How many Wall Street analysts cover XFOR?+
5 analysts have an active rating on X4 Pharmaceuticals Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering XFOR?+
Among analysts who currently cover XFOR, Michael Schmidt of Guggenheim has the strongest overall Quantellect track record (Rank #1). Their current call is Buy with a $12.00 target.
What is X4 Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.19 per share (range $-0.27 – $-0.17) across 5 analysts. Full-year EPS is projected at $-0.73, rising to $-0.82 the following year.
How much revenue is X4 Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $2.3M (range $1.5M – $2.7M). Full-year revenue is projected at $9.6M, growing to $10.3M next year.
Have analysts been upgrading or downgrading XFOR lately?+
As of Jul, 5 of 5 firms rate XFOR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their XFOR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
